Small-molecule Inhibition of the Interactions of the Urokinase Receptor: A Targe
尿激酶受体相互作用的小分子抑制:一个目标
基本信息
- 批准号:8035963
- 负责人:
- 金额:$ 24.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-15 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdhesionsAffinityAntineoplastic AgentsApplications GrantsBindingBiochemicalBiological AssayBlood - brain barrier anatomyBreastCaco-2 CellsCalorimetryCell AdhesionCell Culture TechniquesCell LineCell ProliferationCell Surface ProteinsCell Surface ReceptorsCell surfaceCellsCellular biologyChemicalsClinicClinical PharmacologyCo-ImmunoprecipitationsCollaborationsColon AdenocarcinomaComplementComplexComputational BiologyCore FacilityCrystallizationCytochrome P450DataDevelopmentDockingDrug DesignDrug KineticsDrug TransportEnsureEnvironmentEvaluationEventExhibitsExtracellular Matrix DegradationFluorescence PolarizationFree EnergyFutureG protein coupled receptor kinaseGenerationsGenomicsGlioblastomaH1299HeadHealthHumanIndianaIntegrin BindingIntegrinsInterdisciplinary StudyKnowledgeLeadLettersLibrariesLigandsLiteratureLungMalignant NeoplasmsMammary NeoplasmsMediatingMetabolismMolecularMusNeoplasm MetastasisPenetrationPeptide HydrolasesPermeabilityPharmaceutical PreparationsPharmacologic SubstancePhosphorylationPlasminogenPositioning AttributePrimary NeoplasmProcessPropertyProteinsProteolysisProteomeReportingResearchRewardsRiskRoleScreening procedureSerine ProteaseSerum AlbuminSignal PathwaySignal TransductionSignaling ProteinSiteSolutionsStagingStatistical ModelsStructureSurface Plasmon ResonanceSynthesis ChemistrySystemSystems DevelopmentTestingTherapeuticTitrationsToxic effectTransmembrane DomainTumor Cell InvasionTumor Cell LineU118UrokinaseUrokinase Plasminogen Activator ReceptorValidationWorkXenograft procedureangiogenesisanti-cancer therapeuticbasebiophysical chemistrycell motilitychemical propertychemical synthesischeminformaticscombinatorialcrosslinkdesigndosagedrug discoveryexpectationexperiencefibrosarcomaforginghigh throughput screeningin vivoinhibitor/antagonistinnovationinsightmedical schoolsmigrationmolecular dynamicsneglectneoplastic cellpreventprofessorprogramsprotein protein interactionreceptorreceptor bindingsmall moleculesmall molecule librariesstructural biologysuccessthree dimensional structuretumortumor xenografttyrosine receptorvirtual
项目摘要
DESCRIPTION (provided by applicant): The urokinase receptor (uPAR) is a GPI-anchored protein that serves as a receptor to the serine protease urokinase (uPA). Upon docking to its receptor, uPA is activated, an event that leads to pericellular proteolysis and degradation of the extracellular matrix, a primary barrier between tumor and vasculature. But it is now widely recognized that while uPAR is not capable of signaling, the uPAR/uPA complex interacts and activates a number of cell surface receptors such as integrins, receptor tyrosine kinases, and GPCRs. The uPAR/uPA interaction has been implicated with nearly every step of tumor invasion and metastasis and is therefore a highly suitable target for the development of anti-cancer therapeutics. Previous efforts have concentrated on inhibiting the serine protease activity of uPA with small molecules. But this strategy neglects interactions of the uPAR/uPA complex with cell signaling proteins that are independent of the proteolytic activity of uPA. In this application, we follow a unique approach that seeks to target the uPAR/uPA protein-protein interaction using small molecules with the expectation that these molecules will exhibit the dual effect of blocking proteolysis and signaling. Our initial efforts have been highly rewarding. A preliminary structure-based computational screen has led to 8 active compounds. Cell culture-based studies reveal that a number of these compounds block MDA-MB-231 tumor cell adhesion, migration, and invasion. Compounds were also found to inhibit lung H1299 tumor cell proliferation. Biochemical analyses reveal that that these compounds also block integrin binding to the uPAR/uPA complex. Our objective in this grant application is to optimize the pharmacokinetic properties and potency of three of these compounds to block tumor invasion and metastasis in vivo. To that end, a multidisciplinary research program involving computational biology, synthetic chemistry, biophysical chemistry, structural biology, and cell biology will be followed. The first aim will consist of creating a virtual combinatorial library of compounds based on our lead molecules, ranking these compounds based on predicted potency, and predicting pharmacokinetic properties of the most potent compounds. The second aim will involve the chemical synthesis of the most promising compounds, followed by an assessment of their activity using a fluorescence polarization assay. The most potent compounds are further characterized with isothermal titration calorimetry. We then solve the three-dimensional structure of these compounds in complex with the urokinase receptor using x-ray diffraction. Finally, the third aim will consist of assessing the cellular efficacy of the most selective and potent inhibitors in MDA-MB-231 and other tumor cell lines, and to perform preliminary in vivo dosage studies to set the stage for future studies in mice xenografts. PUBLIC HEALTH RELEVANCE: The urokinase receptor is a cell surface receptor that binds and activates various proteins. These interactions lead, among other things, to the degradation of a protective layer between a primary tumor and the vasculature, as well as the adhesion and migration of cells. These processes are hallmarks of cancer metastasis. Small molecules with drug-like properties that prevent the urokinase receptor from interacting with its binding partners could lead to highly effective therapeutics to prevent tumor metastasis.
描述(申请人提供):尿激酶受体(uPAR)是一种GPI锚定蛋白,作为丝氨酸蛋白酶尿激酶(uPA)的受体。在与其受体对接后,uPA被激活,这是导致细胞周围蛋白水解和细胞外基质降解的事件,细胞外基质是肿瘤和脉管系统之间的主要屏障。但现在广泛认识到,虽然uPAR不能进行信号传导,但uPAR/uPA复合物相互作用并激活许多细胞表面受体,如整联蛋白、受体酪氨酸激酶和GPCR。uPAR/uPA相互作用几乎涉及肿瘤侵袭和转移的每一步,因此是开发抗癌疗法的高度合适的靶标。以前的努力集中在用小分子抑制uPA的丝氨酸蛋白酶活性。但这种策略忽略了uPAR/uPA复合物与细胞信号蛋白的相互作用,这些蛋白不依赖于uPA的蛋白水解活性。在本申请中,我们遵循一种独特的方法,该方法寻求使用小分子靶向uPAR/uPA蛋白质-蛋白质相互作用,期望这些分子将表现出阻断蛋白质水解和信号传导的双重作用。我们最初的努力是非常有益的。初步的基于结构的计算筛选导致了8个活性化合物。基于细胞培养的研究表明,许多这些化合物阻断MDA-MB-231肿瘤细胞粘附、迁移和侵袭。还发现化合物抑制肺H1299肿瘤细胞增殖。生物化学分析表明,这些化合物也阻断整合素与uPAR/uPA复合物的结合。我们在这项资助申请中的目标是优化这些化合物中的三种的药代动力学特性和效力,以阻断体内肿瘤侵袭和转移。为此,将遵循涉及计算生物学,合成化学,生物物理化学,结构生物学和细胞生物学的多学科研究计划。第一个目标将包括基于我们的先导分子创建化合物的虚拟组合库,基于预测的效力对这些化合物进行排名,并预测最有效化合物的药代动力学特性。第二个目标将涉及最有希望的化合物的化学合成,然后使用荧光偏振测定法评估其活性。最有效的化合物进一步用等温滴定量热法表征。然后,我们解决了这些化合物的三维结构与尿激酶受体的复杂使用X-射线衍射。最后,第三个目标将包括评估MDA-MB-231和其他肿瘤细胞系中最具选择性和最有效的抑制剂的细胞功效,并进行初步的体内剂量研究,为小鼠异种移植物的未来研究奠定基础。公共卫生相关性:尿激酶受体是一种细胞表面受体,结合并激活各种蛋白质。这些相互作用尤其导致原发性肿瘤和脉管系统之间的保护层的降解,以及细胞的粘附和迁移。这些过程是癌症转移的标志。具有药物样性质的小分子可以阻止尿激酶受体与其结合伴侣相互作用,这可能导致高度有效的治疗方法来预防肿瘤转移。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Samy Meroueh其他文献
Samy Meroueh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Samy Meroueh', 18)}}的其他基金
A Fragment-Based Strategy for K-RAS Covalent Inhibitors
基于片段的 K-RAS 共价抑制剂策略
- 批准号:
10290524 - 财政年份:2021
- 资助金额:
$ 24.8万 - 项目类别:
A Fragment-Based Strategy for K-RAS Covalent Inhibitors
基于片段的 K-RAS 共价抑制剂策略
- 批准号:
10443837 - 财政年份:2021
- 资助金额:
$ 24.8万 - 项目类别:
A Fragment-Based Strategy for K-RAS Covalent Inhibitors
基于片段的 K-RAS 共价抑制剂策略
- 批准号:
10653029 - 财政年份:2021
- 资助金额:
$ 24.8万 - 项目类别:
Small Molecules to Promote Regeneration and Recovery Following Spinal Cord Injury
小分子促进脊髓损伤后的再生和恢复
- 批准号:
10514585 - 财政年份:2020
- 资助金额:
$ 24.8万 - 项目类别:
Small Molecules to Promote Regeneration and Recovery Following Spinal Cord Injury
小分子促进脊髓损伤后的再生和恢复
- 批准号:
10016825 - 财政年份:2020
- 资助金额:
$ 24.8万 - 项目类别:
Small Molecules to Promote Regeneration and Recovery Following Spinal Cord Injury
小分子促进脊髓损伤后的再生和恢复
- 批准号:
10293587 - 财政年份:2020
- 资助金额:
$ 24.8万 - 项目类别:
Small-Molecule Antagonists of Ral GTPases in Cancer
癌症中 Ral GTP 酶的小分子拮抗剂
- 批准号:
9896783 - 财政年份:2016
- 资助金额:
$ 24.8万 - 项目类别:
Small-Molecule Antagonists of Ral GTPases in Cancer
癌症中 Ral GTP 酶的小分子拮抗剂
- 批准号:
9236177 - 财政年份:2016
- 资助金额:
$ 24.8万 - 项目类别:
Small-molecule Inhibition of the Interactions of the Urokinase Receptor: A Targe
尿激酶受体相互作用的小分子抑制:一个目标
- 批准号:
7653278 - 财政年份:2009
- 资助金额:
$ 24.8万 - 项目类别:
Small-molecule Inhibition of the Interactions of the Urokinase Receptor: A Targe
尿激酶受体相互作用的小分子抑制:一个目标
- 批准号:
8233459 - 财政年份:2009
- 资助金额:
$ 24.8万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 24.8万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 24.8万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 24.8万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 24.8万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 24.8万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 24.8万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 24.8万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 24.8万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 24.8万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 24.8万 - 项目类别:
Continuing Grant